Legacy Pharma

What Legacy Pharma does

Legacy Pharma Inc. SEZC is a privately held pharmaceutical company that distributes established prescription pharmaceutical products to patients in the United States. The company is incorporated as a Cayman Islands Special Economic Zone Company (SEZC), with US operations executed through wholly-owned subsidiary Legacy Pharma USA Inc., headquartered in Scottsdale, Arizona, and additional subsidiaries Allegis Pharmaceuticals and Marnel Pharmaceuticals that house acquired brand assets. The portfolio comprises approximately ten prescription brands spanning cardiovascular (Betapace, Betapace AF — sotalol HCl antiarrhythmics), neurology/spasticity (Zanaflex — tizanidine), dermatology (Ala-Scalp, Crotan, Naftin, Analpram, Pramosone), gastroenterology (Motofen), and — most recently — respiratory medicine following the February 2025 acquisition of InterMune, Inc. and US rights to Esbriet (pirfenidone) for idiopathic pulmonary fibrosis from Roche.

Underlying technology consists of FDA-approved small-molecule formulations rather than a proprietary platform; the company's defensibility rests on regulatory dossiers, brand recognition, and an established US pharmaceutical distribution network reaching pharmacies and healthcare systems, supported by product-branded websites for each major asset. Core technology is not explicitly disclosed in the input, consistent with a branded-pharma distributor model rather than a discovery or novel-platform model.

Commercially, Legacy Pharma runs a sales-led go-to-market through traditional pharmaceutical channels, distributing into US pharmacies and healthcare providers, with marketing concentrated on prescriber outreach and product-branded information sites. Pricing is not publicly disclosed and is effectively set by healthcare providers, insurance plans, and pharmacy benefit managers. Revenue is not publicly reported; the company is private with no disclosed funding rounds, and the most significant recent commercial event is the InterMune/Esbriet acquisition, which expands the addressable US respiratory market presence.

Name

Legacy Pharma

Legal name

Legacy Pharma Inc. SEZC

Website

https://legacypharmainc.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Legacy Pharma Inc. SEZC is a privately held pharmaceutical company that distributes established prescription pharmaceutical brands — including Betapace, Zanaflex, and Esbriet — to US patients through traditional pharmacy and healthcare-system channels.

Ownership category

akta.pro rank

Product category

Branded Prescription Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

Keywords

• Prescription pharmaceuticals
• Branded drug distribution
• Specialty pharmaceuticals
• Established drug brands
• US pharmaceutical supply

Headquarters

HQ city

George Town

HQ country

Cayman Islands

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Product Distribution: Legacy Pharma generates revenue through the distribution of established prescription pharmaceutical products. The company maintains portfolios of branded pharmaceutical products including Betapace, Zanaflex, and acquired rights to Esbriet, distributing them through pharmaceutical supply chains to patients who need them.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Legacy Pharma Inc. SEZC is a pharmaceutical company that distributes established prescription pharmaceutical products. It maintains a portfolio of branded prescription drugs — including Betapace and Betapace AF (sotalol HCl antiarrhythmics), Zanaflex (tizanidine for spasticity), and acquired brands such as Esbriet (pirfenidone for idiopathic pulmonary fibrosis) plus the Allegis and Marnel product lines — and works to ensure these in-demand brands remain available to patients through US pharmaceutical supply channels.

Product overview

Legacy Pharma Inc. SEZC is a pharmaceutical company that distributes established prescription pharmaceutical products. The portfolio includes Betapace and Betapace AF (antiarrhythmic drugs for cardiac arrhythmias), Zanaflex (muscle relaxant for spasticity management), and additional acquired brands including Esbriet (acquired February 2025 via InterMune acquisition), Ala-Scalp, Crotan, Analpram, Motofen, Naftin, and Pramosone. The company focuses on ensuring in-demand prescription brands remain available for distribution to US patients.

Differentiator

Problem solved

Functional benefit

Brands

• Betapace: Antiarrhythmic drug (sotalol HCl) used for treatment of life-threatening ventricular arrhythmias and maintenance of normal sinus rhythm in patients with atrial fibrillation or flutter.
• Betapace AF
• Zanaflex

Products and services

• Betapace Betapace (sotalol HCl) is an antiarrhythmic drug used for the maintenance of normal sinus rhythm in patients with atrial fibrillation or flutter (AFIB/AFL) and the treatment of life-threatening ventricular arrhythmias.
• Betapace AF Betapace AF (sotalol HCl) is an antiarrhythmic indicated for maintenance of normal sinus rhythm in patients with atrial fibrillation or flutter.
• Zanaflex Zanaflex (tizanidine hydrochloride) is a central alpha-2-adrenergic agonist indicated for the management of spasticity associated with multiple sclerosis and spinal cord injuries, available as capsules (2mg, 4mg, 6mg) and tablets (4mg).
• Ala-Scalp Prescription pharmaceutical product in Legacy Pharma's portfolio held under the Allegis Pharmaceuticals subsidiary.
• Crotan Prescription pharmaceutical product in Legacy Pharma's portfolio held under the Marnel Pharmaceuticals subsidiary.
• Analpram Prescription pharmaceutical product in Legacy Pharma's portfolio.
• Motofen Prescription pharmaceutical product in Legacy Pharma's portfolio.
• Naftin Prescription pharmaceutical product in Legacy Pharma's portfolio.
• Pramosone Prescription pharmaceutical product in Legacy Pharma's portfolio.
• Esbriet Esbriet (pirfenidone) is a prescription pharmaceutical indicated for the treatment of idiopathic pulmonary fibrosis, distributed in the United States by Legacy Pharma following its acquisition of InterMune, Inc.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Roche / InterMune, Inc.coreStrategic or Co-development Partner · 1 February 2025Legacy Pharma acquired InterMune, Inc. and obtained US rights to Esbriet (pirfenidone), a treatment for idiopathic pulmonary fibrosis. This acquisition represents a significant expansion of Legacy Pharma's pharmaceutical product portfolio.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Endo International: Specialty pharma focused on established branded and generic prescription products across therapeutic categories including neurology and pain. Directly comparable to Legacy Pharma's strategy of maintaining and distributing mature branded pharmaceuticals.
• Alvogen: Privately held specialty pharmaceutical company focused on acquiring and distributing established branded and specialty prescription products across multiple therapeutic areas. Closely analogous offshore-domiciled, brand-acquisition model.
• Lannett Co. US-focused pharmaceutical company distributing branded and generic prescription products through established US channels. Overlapping go-to-market and product-maintenance model.
• Bausch Health Companies: Diversified specialty pharma built around acquiring and operating legacy branded prescription products. Closely analogous to Legacy Pharma's portfolio-acquisition approach in cardiology, neurology, and specialty categories.
• Amneal Pharmaceuticals: Specialty and generic pharmaceutical company with a meaningful branded specialty franchise alongside generics. Comparable mix of established branded products distributed through US pharmaceutical supply channels.
• Mallinckrodt Pharmaceuticals: Specialty pharmaceutical company that owns and markets established branded prescription products across multiple therapeutic areas. Highly comparable business model to Legacy Pharma's brand-maintenance focus on in-demand specialty drugs.
• ANI Pharmaceuticals: Small-cap specialty pharma that markets established prescription brands and specialty generics across multiple therapeutic areas. Highly comparable scale and brand-acquisition strategy to Legacy Pharma.

Broad incumbents

• Galderma: Global specialty pharma pure-play in dermatology that owns and markets established branded prescription dermatology products. Overlaps with Legacy Pharma's dermatology/topical brands (Naftin, Pramosone, Analpram, Ala-Scalp, Crotan).

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/legacy-pharma-inc

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Legacy Pharma